Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort

Bone Safety of Dolutegravir-Containing Regimens in People Living with HIV: Results from a Real-World Cohort

Paolo Bonfanti,1 Andrea De Vito,2 Elena Ricci,3 Barbara Menzaghi,4 Giancarlo Orofino,5 Nicola Squillace,1 Chiara Molteni,6 Giuseppe Vittorio De Socio,7 Elena Salomoni,8 Benedetto Maurizio Celesia,9 Chiara Dentone,10 Valeria Colombo,11 Giordano Madeddu2 1Infectious Diseases Unit ASST-MONZA, San Gerar...

Full description

Bibliographic Details
Main Authors:	Bonfanti P, De Vito A, Ricci E, Menzaghi B, Orofino G, Squillace N, Molteni C, De Socio GV, Salomoni E, Celesia BM, Dentone C, Colombo V, Madeddu G
Format:	Article
Language:	English
Published:	Dove Medical Press 2020-07-01
Series:	Infection and Drug Resistance
Subjects:	hiv infection dolutegravir bone mineral density real life setting adverse events dxa scan
Online Access:	https://www.dovepress.com/bone-safety-of-dolutegravir-containing-regimens-in-people-living-with--peer-reviewed-article-IDR

Similar Items

Lipid profile improvement in virologically suppressed HIV-1-infected patients switched to dolutegravir/abacavir/lamivudine: data from the SCOLTA project
by: Bagella P, et al.
Published: (2019-05-01)

A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data
by: Amedeo F. Capetti, et al.
Published: (2017-09-01)

Careful consideration when responding to new data: dolutegravir and pregnancy
by: C. Foster, et al.
Published: (2018-07-01)

Treatment Satisfaction and Its Associated Factors of Dolutegravir Based Regimen in a Resource Limited Setting
by: Mehari EA, et al.
Published: (2021-06-01)

Suicidal overdose of dolutegravir: A case report
by: Rahul Daimari, et al.
Published: (2018-06-01)

Efficacy of switching to dolutegravir plus rilpivirine, the small-tablet regimen, in patients with dysphagia: two case reports
by: Takefumi Suzuki, et al.
Published: (2017-09-01)

Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort
by: Phillip Chan, et al.
Published: (2020-01-01)

Dolutegravir/rilpivirine for the treatment of HIV-1 infection
by: Dowers E, et al.
Published: (2018-11-01)

DOLUTEGRAVIR efficacy in HIV infected patients
by: Dumitru Irina Magdalena, et al.
Published: (2015-02-01)

Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
by: Zamora FJ, et al.
Published: (2019-10-01)

A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study
by: Spagnuolo V, et al.
Published: (2019-01-01)

Cost-effectiveness analysis of dolutegravir plus backbone compared with raltegravir plus backbone, darunavir+ritonavir plus backbone and efavirenz/tenofovir/emtricitabine in treatment naïve and experienced HIV-positive patients
by: Restelli U, et al.
Published: (2017-06-01)

Will Drug Resistance against Dolutegravir in Initial Therapy Ever Occur?
by: Mark eWainberg, et al.
Published: (2015-04-01)

The Effect of Moderate- and High-Fat Meals on the Bioavailability of Dolutegravir/Rilpivirine Fixed-Dose Combination Tablet
by: Mehta R, et al.
Published: (2020-06-01)

Two cases of neural tube defects with dolutegravir use at conception in south Brazil
by: Regis Kreitchmann, et al.
Published: (2021-03-01)

An effective stability indicating RP-HPLC method for simultaneous estimation of Dolutegravir and Lamivudine in bulk and their tablet dosage form
by: Ramreddy Godela, et al.
Published: (2020-04-01)

Is pricing of dolutegravir equitable? A comparative analysis of price and country income level in 52 countries
by: Joel Sim, et al.
Published: (2018-10-01)

Physiologically Relevant Concentrations of Dolutegravir, Emtricitabine, and Efavirenz Induce Distinct Metabolic Alterations in HeLa Epithelial and BV2 Microglial Cells
by: Joseph W. George, et al.
Published: (2021-05-01)

High rates of transmitted NNRTI resistance among persons with acute HIV infection in Malawi: implications for first-line dolutegravir scale-up
by: Sarah E. Rutstein, et al.
Published: (2019-02-01)

Changes in Inflammatory and Atherogenesis Biomarkers with the 2-Drug Regimen Dolutegravir plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People with HIV-1: A Systematic Literature Review
by: Barber, T.J, et al.
Published: (2022)

Development and validation of stability-indicating HPLC method for simeltaneous determination of Lamivudine, Tenofovir, and Dolutegravir in bulk and their tablet dosage form
by: Nagasarapu Mallikarjuna Rao, et al.
Published: (2015-12-01)

Impact of UGT1A1 gene polymorphisms on plasma dolutegravir trough concentrations and neuropsychiatric adverse events in Japanese individuals infected with HIV-1
by: Hiroki Yagura, et al.
Published: (2017-09-01)

Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients
by: Yogesh Suresh Punekar, et al.
Published: (2019-12-01)

Remission of an HHV8-related extracavitary primary effusion lymphoma in an HIV-positive patient during antiretroviral treatment containing dolutegravir
by: Laura Campogiani, et al.
Published: (2019-07-01)

Case report: Emergence of dolutegravir resistance in a patient on second-line antiretroviral therapy
by: Kairoonisha Mahomed, et al.
Published: (2020-07-01)

Is Resistance to Dolutegravir Possible When This Drug Is Used in First-Line Therapy?
by: Thibault Mesplède, et al.
Published: (2014-08-01)

The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study
by: Calcagno, A., et al.
Published: (2022)

A new validated stability-indicating RP-HPLC method for simultaneous quantification of dolutegravir and lamivudine in bulk and pharmaceutical dosage form
by: Khaleel Noorbasha, et al.
Published: (2020-07-01)

Spectrophotometric quantification of dolutegravir based on redox reaction with Fe3+/1,10-phenanthroline
by: Swathi Naraparaju, et al.
Published: (2020-11-01)

Dolutegravir-based anti-retroviral therapy is effective and safe in HIV–infected paediatric patients
by: Eugenia Bruzzese, et al.
Published: (2018-03-01)

Virologic outcomes of switching to boosted darunavir plus dolutegravir with respect to history of drug resistance
by: Eva Wolf, et al.
Published: (2021-09-01)

Two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 treatment-naïve, virologically-suppressed patients: Latest evidence from the literature on their efficacy and safety
by: Valeria Cento, et al.
Published: (2020-03-01)

Preparation of the Key Dolutegravir Intermediate via MgBr<sub>2</sub>-Promoted Cyclization
by: Jiahui Kong, et al.
Published: (2021-05-01)

O papel do dolutegravir na terapia antiretroviral
by: Tamyres dos Santos Vieira, et al.
Published: (2019-06-01)

Virologic outcomes of switching to dolutegravir functional mono- or dual therapy with a non-cytosine nucleoside analog: a retrospective study of treatment-experienced, patients living with HIV
by: Charlotte-Paige Rolle, et al.
Published: (2021-05-01)

Reply to Das and Berkhout, “How Polypurine Tract Changes in the HIV-1 RNA Genome Can Cause Resistance against the Integrase Inhibitor Dolutegravir”
by: Isabelle Malet, et al.
Published: (2018-05-01)

Dolutegravir-based antiretroviral therapy in a severely overweight child with a multidrug-resistant human immunodeficiency virus infection. A case report and review
by: N. Wagner, et al.
Published: (2015-07-01)

Modern antiretroviral regimens
by: A. V. Kravchenko
Published: (2016-12-01)

HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol
by: Ezechiel Ngoufack Jagni Semengue, et al.
Published: (2020-04-01)

Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda
by: Yussif Alhassan, et al.
Published: (2020-08-01)